Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.010
Buy
RSI(14)
51.044
Neutral
STOCH(KDJ)(9,3,3)
22.150
Neutral
ATR(14)
0.186
High Vlolatility
CCI(14)
51.566
Neutral
Williams %R
83.238
Oversold
TRIX(12,20)
0.238
Sell
StochRSI(14)
36.838
Sell
Trinity Biotech PLC
TRIB1.020USD
-0.260-20.31%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
8.46MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Trinity Biotech PLC
Currency: USD Updated: 2025-12-24Key Insights
Trinity Biotech PLC's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 151/206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Trinity Biotech PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Trinity Biotech PLC Highlights
StrengthsRisks
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Growing
The company is in a growing phase, with the latest annual income totaling USD 61.55M.
Fairly Valued
The company’s latest PE is -0.20, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 972.36K shares, increasing 42.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 171.36K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 8.62.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Trinity Biotech PLC is 6.08, ranking 175/206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 15.15M, representing a year-over-year increase of 3.24%, while its net profit experienced a year-over-year increase of 29.19%.
Score
Financials
3.54
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.93
Operational Efficiency
6.00
Growth Potential
5.83
Shareholder Returns
7.09
Trinity Biotech PLC's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Trinity Biotech PLC is 6.90, ranking 141/206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.20, which is -48.99% below the recent high of -0.10 and -171.35% above the recent low of -0.54.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 151/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24No earnings forecast score is currently available for Trinity Biotech PLC. The Healthcare Equipment & Supplies industry's average is 7.77.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Trinity Biotech PLC is 6.46, ranking 139/206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.56 and the support level at 0.68, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.006
Buy
MA10
0.999
Buy
MA20
1.022
Sell
MA50
0.973
Buy
MA100
1.094
Sell
MA200
0.888
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Trinity Biotech PLC is 3.00, ranking 135/206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 12.90%, representing a quarter-over-quarter decrease of 24.04%. The largest institutional shareholder is James Simons, holding a total of 171.36K shares, representing 4.60% of shares outstanding, with 1017.52% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
MiCo IVD Holdings, LLC
Perceptive Advisors LLC
Hunter Associates Investment Management LLC
Two Sigma Investments, LP
Moss Adams Wealth Advisors LLC
Cambridge Investment Research Advisors, Inc.
Raymond James & Associates, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Trinity Biotech PLC is 1.67, ranking 182/206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.53. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.53
VaR
+7.73%
240-Day Maximum Drawdown
+61.76%
240-Day Volatility
+176.97%
Return
Best Daily Return
60 days
+43.50%
120 days
+89.05%
5 years
+89.05%
Worst Daily Return
60 days
-20.31%
120 days
-20.31%
5 years
-29.92%
Sharpe Ratio
60 days
+0.45
120 days
+1.05
5 years
-0.17
Risk Assessment
Maximum Drawdown
240 days
+61.76%
3 years
+91.18%
5 years
+97.79%
Return-to-Drawdown Ratio
240 days
+0.35
3 years
-0.30
5 years
-0.20
Skewness
240 days
+4.94
3 years
+4.29
5 years
+4.41
Volatility
Realised Volatility
240 days
+176.97%
5 years
+129.80%
Standardised True Range
240 days
+9.71%
5 years
+38.97%
Downside Risk-Adjusted Return
120 days
+293.63%
240 days
+293.63%
Maximum Daily Upside Volatility
60 days
+200.87%
Maximum Daily Downside Volatility
60 days
+97.96%
Liquidity
Average Turnover Rate
60 days
+3.79%
120 days
+1.93%
5 years
--
Turnover Deviation
20 days
+861.59%
60 days
+284.98%
120 days
+95.76%
Peer Comparison
Healthcare Equipment & Supplies
Trinity Biotech PLC
TRIB
4.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Trinity Biotech PLC?
The TradingKey Stock Score provides a comprehensive assessment of Trinity Biotech PLC based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Trinity Biotech PLC’s performance and outlook.
How do we generate the financial health score of Trinity Biotech PLC?
To generate the financial health score of Trinity Biotech PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Trinity Biotech PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Trinity Biotech PLC.
How do we generate the company valuation score of Trinity Biotech PLC?
To generate the company valuation score of Trinity Biotech PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Trinity Biotech PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Trinity Biotech PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Trinity Biotech PLC.
How do we generate the earnings forecast score of Trinity Biotech PLC?
To calculate the earnings forecast score of Trinity Biotech PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Trinity Biotech PLC’s future.
How do we generate the price momentum score of Trinity Biotech PLC?
When generating the price momentum score for Trinity Biotech PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Trinity Biotech PLC’s prices. A higher score indicates a more stable short-term price trend for Trinity Biotech PLC.
How do we generate the institutional confidence score of Trinity Biotech PLC?
To generate the institutional confidence score of Trinity Biotech PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Trinity Biotech PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Trinity Biotech PLC.
How do we generate the risk management score of Trinity Biotech PLC?
To assess the risk management score of Trinity Biotech PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Trinity Biotech PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Trinity Biotech PLC.
